BioCentury
ARTICLE | Company News

Active Biotech, Teva deal

February 15, 2010 8:00 AM UTC

Teva will now have exclusive, worldwide rights to develop and commercialize Active Biotech's laquinimod. The companies added the Nordic and Baltic regions, which were excluded from the original 2004 d...